ArticleFrontiers in oncology2025
Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In locally advanced non-small cell lung cancer (LA-NSCLC), durvalumab as consolidation therapy following definitive chemoradiotherapy (CRT) was established as the standard of care. Given the heterogeneity of patients with LA-NSCLC, the present study evaluated the efficacy and safety of durvalumab in a real-world, multicenter observational study. Methods: Patients with LA-NSCLC, whose disease had not progressed following CRT and receiving ≥1 dose of durvalumab as part of the expanded access program (EAP) in Thailand and outside EAP, were included. In addition to descriptive statistics, survival probability was determined using the Kaplan-Meier method. Results: A total of 82 patients from 12 centers in Thailand were enrolled. The median age was 63 years, 74% were men, 72% had non-squamous NSCLC, and 20% of patients had an epidermal growth factor receptor (EGFR) mutation. Only 13.4% of patients were tested for programmed death-ligand 1 (PD-L1), and 54.5% had PD-L1 expression. Most patients (84%) received concurrent CRT, and carboplatin/paclitaxel was the most commonly used. Of the patients, 89% received radiotherapy (RT) dose ≥60 Gy with a median time of durvalumab initiation from the end of RT being 42 days. Overall, 57% of patients completed the 12-month treatment with a median of 24 cycles. Objective response rate (ORR) and disease control rate (DCR) were 41.3% and 86.7%, respectively. With a median follow-up time of 43.3 months, 2-year progression-free survival (PFS) and 2-year time to second objective disease progression (PFS2) were 63.1% and 81.6%, respectively. Immune-related adverse events (irAEs) of any grade and grade ≥ 3 were 25.6% and 9.8%, respectively. Pneumonitis was the most frequent irAE (17%), and 6% were grade ≥ 3, leading to discontinuation in six patients (7.3%). Conclusions: Durvalumab following definitive CRT demonstrated promising outcomes and was well-tolerated in this real-world study. These findings support the utilization of durvalumab for enhancing outcomes in patients with unresectable LA-NSCLC within Asian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.